Studies and controlled observational scientific investigations performed on more than 1,000 men and women at dermatology and university clinics in Germany and internationally have verified the effectiveness of Thymuskin on all forms of hair loss.
The success rate for androgenetic hair loss (hereditary hair loss often referred to as male pattern hair loss or female pattern hair loss), telogen effluvium (hair thinning or hair shedding), alopecia areata (spot baldness) and mildforms of cytostatic drug-induced alopecia (chemotherapy related hair loss) averages well over 90%, with no side effects involved even with long-term use.
Androgenetic Alopecia (hereditary hair loss)
A study was undertaken investigating the effectiveness and tolerability of Thymuskin (serum and shampoo) in the initial phase of androgenetic alopecia (AGA) over a period of six months. The study included 364 test subjects.
The patients used the serum once a day and the shampoo three times a week over a total period of 24 weeks.
- After 6 months hair loss reduced in an average of 96% of patients
- Sebororrohea (excessively oily skin) and erythema (skin irritation) improved in at least 89% of patients in each case
- Itching was eliminated in 74% of women and 75% of men
Chronic Telogen Effluvium (hair thinnning / shedding)
A study was undertaken investigating the effectiveness and tolerability of Thymuskin (serum and shampoo) in 184 women and 57 men with chronic telogen effluvium (chronic TE) over a period of six months.
- Hair loss reduced in an average of 99% of patients
- Seborrhoea and erythema improved in at least 93% of women and 76 %of men
- Itching eliminated in 80% of women and 51% of men
Alopecia Areata (Circular hair loss or spot baldness)
Two studies were performed investigating Thymuskin’s effectiveness in 16 patients with alopecia areata (AA) over a period of 12 months.
- Number of hairs lost daily reduced by 96%
- New hair growth in 65% - 86% of patients
- Full remission in 40% of patients
Cytostatic Drud-Induced Alopecia (Chemotherapy induced hair loss)
A study was undertaken to investigate the extent to which hair loss as a side effect of cytostatic chemotherapy can be affected by the prophylactic application of Thymuskin alongside the treatment.
- Thymuskin is 3 times more likely to prevent hair loss or total reversible alopecia under cytostatic (chemotherapy) therapy.
- With ‘mild’ cytostatic therapy, Thymuskin maintains hair condition in up to 94% of patients.
- Thymuskin use can maintain hair condition significantly more often for patients undergoing ‘mild’ cytostatic therapy (5-fluorouracil) than for patients undergoing ‘aggressive’ cytostatic therapy (Adriamycin).
- The positive effects of Thymuskin on hair condition are more significant for patients with breast or colon cancer than for patients with oesophageal or stomach cancer.
If you'd like further details regarding the clinical evidence for using Thymuskin to help prevent hair loss please contact us on hello@cancerpal.co.uk